BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33120793)

  • 1. Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
    Hu S; Zou D; Zhou D; Zhang Y; Wang W; Zhang W
    Medicine (Baltimore); 2020 Oct; 99(43):e22788. PubMed ID: 33120793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
    Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
    Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.
    Yang D; Zhang WP; Yang JM; He MX; Cheng C; Chen J
    Medicine (Baltimore); 2018 Dec; 97(49):e13093. PubMed ID: 30544372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
    Yang X; Min X; He W
    Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.
    Wu P; Ma T; Chen Y; Wang F; Chen Y; Gao J; Zhou Z; Jia Y
    Anticancer Drugs; 2021 Sep; 32(8):886-889. PubMed ID: 34145178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Nedved A; Maddocks K; Nowakowski GS
    Oncologist; 2023 Mar; 28(3):199-207. PubMed ID: 36648324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
    Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
    Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
    Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
    Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
    Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
    Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
    Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Li C; Sun Y; Wang J; Tang L; Jiang H; Guo T; Liu L; Wu Y; Ai L; Xia L; Wu J; Lin Z; Qian Q; Hu Y; Mei H
    Front Immunol; 2021; 12():599493. PubMed ID: 34113336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.